Tag: NeoChord

NeoChord Announces Positive 1-year Follow-Up Data with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor

ST. LOUIS PARK, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company, is leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation with more than a decade of commercial experience in treating over 1,800 patients globally with the transapical technology. Based on this clinical […]

NeoChord Appoints Martin B. Leon, M.D. as Executive Chair of the U.S. Early Feasibility Study of the NeoChord Transcatheter NeXuS System

ST. LOUIS PARK, Minn., March 14, 2022 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced the appointment of Martin B. Leon, M.D. as Executive Chair of the U.S. early feasibility study (EFS) of the NeoChord Transcatheter […]

NeoChord Announces Positive 30-day Results with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor

ST. LOUIS PARK, Minn., Nov. 22, 2021 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced positive 30-day results following the first successful worldwide procedure using multiple chords to a single anchor. The procedure was completed with the […]

NeoChord Announces Successful Completion of First in Human Procedure with its NeoChord NeXuS Transcatheter Mitral Chordal Repair Technology

ST. LOUIS PARK, Minn., Oct. 04, 2021 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr). The first-in-human procedure was performed […]

NeoChord Raises Additional Financing to Drive Catheter-based Program Development, Bringing Total Series D Funding to over $32 Million

ST. LOUIS PARK, Minn., April 23, 2019 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has secured additional funding as an extension of its Series D equity financing, which was announced in November of […]

NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs

ST. LOUIS PARK, Minn., Nov. 05, 2018 (GLOBE NEWSWIRE) —  NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has completed a $25 million Series D equity financing. Proceeds from the financing will be used to accelerate […]

NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China

ST. LOUIS PARK, Minn., Sept. 04, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced that it has successfully treated the first patients in Asia using the NeoChord procedure at Queen Mary Hospital (QMH) in Hong […]

NeoChord Announces a Research Collaboration With the Skirball Center for Innovation at the Cardiovascular Research Foundation

ST. LOUIS PARK, Minn., Jan. 22, 2018 (GLOBE NEWSWIRE) — NeoChord, a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced a research collaboration with the Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF)to accelerate development of the company’s transcatheter program. “We are delighted to […]

Andrew ElBardissi, M.D. Named to NeoChord Board of Directors

ST. LOUIS PARK, Minn., July 10, 2017 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of Andrew ElBardissi, M.D. to its Board of Directors, effective immediately. Dr. ElBardissi is replacing Avi Kometz, MD as the representative from […]